KR20220057637A - 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 - Google Patents

벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 Download PDF

Info

Publication number
KR20220057637A
KR20220057637A KR1020227013308A KR20227013308A KR20220057637A KR 20220057637 A KR20220057637 A KR 20220057637A KR 1020227013308 A KR1020227013308 A KR 1020227013308A KR 20227013308 A KR20227013308 A KR 20227013308A KR 20220057637 A KR20220057637 A KR 20220057637A
Authority
KR
South Korea
Prior art keywords
benralizumab
antigen
binding fragment
asthma
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227013308A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 워드
로린 로스코스
빙 왕
도널드 래이블
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20220057637A publication Critical patent/KR20220057637A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
KR1020227013308A 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 Ceased KR20220057637A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
US61/864,944 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab
KR1020167006559A KR102390714B1 (ko) 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167006559A Division KR102390714B1 (ko) 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법

Publications (1)

Publication Number Publication Date
KR20220057637A true KR20220057637A (ko) 2022-05-09

Family

ID=52448837

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227013308A Ceased KR20220057637A (ko) 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
KR1020167006559A Active KR102390714B1 (ko) 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167006559A Active KR102390714B1 (ko) 2013-08-12 2014-08-07 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법

Country Status (26)

Country Link
US (2) US9441037B2 (enExample)
EP (1) EP3033101B1 (enExample)
JP (4) JP6746495B2 (enExample)
KR (2) KR20220057637A (enExample)
CN (2) CN105451760A (enExample)
AU (2) AU2014306956B2 (enExample)
BR (1) BR112016002401A8 (enExample)
CA (1) CA2918105C (enExample)
CY (1) CY1122132T1 (enExample)
DK (1) DK3033101T3 (enExample)
ES (1) ES2716906T3 (enExample)
HK (1) HK1221644A1 (enExample)
HR (1) HRP20190405T1 (enExample)
HU (1) HUE042607T2 (enExample)
LT (1) LT3033101T (enExample)
ME (1) ME03348B (enExample)
MX (1) MX368508B (enExample)
PL (1) PL3033101T3 (enExample)
PT (1) PT3033101T (enExample)
RS (1) RS58404B1 (enExample)
RU (1) RU2676333C2 (enExample)
SG (2) SG11201600481UA (enExample)
SI (1) SI3033101T1 (enExample)
SM (1) SMT201900163T1 (enExample)
TR (1) TR201903312T4 (enExample)
WO (1) WO2015023504A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.
KR102337599B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−4およびペリオスチン
PL3565823T3 (pl) 2017-01-04 2024-10-28 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Peptydy S-arestyn oraz ich zastosowanie terapeutyczne
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018032A (en) 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
DK3072525T3 (en) * 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
CN102365017A (zh) * 2009-11-18 2012-02-29 美迪诺亚公司 哮喘急性恶化的治疗及减少哮喘患者住院治疗的可能性
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
KR102337599B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
MX368474B (es) 2013-08-12 2019-10-04 Astrazeneca Ab Uso de benralizumab para mejorar síntomas de asma.

Also Published As

Publication number Publication date
KR20160042121A (ko) 2016-04-18
EP3033101B1 (en) 2018-12-19
HUE042607T2 (hu) 2019-07-29
CA2918105A1 (en) 2015-02-19
KR102390714B1 (ko) 2022-04-26
ES2716906T3 (es) 2019-06-17
BR112016002401A2 (pt) 2017-09-12
RU2016108723A (ru) 2017-09-19
RU2676333C2 (ru) 2018-12-28
MX368508B (es) 2019-10-07
DK3033101T3 (en) 2019-04-08
SG10202005560UA (en) 2020-07-29
BR112016002401A8 (pt) 2018-06-12
CA2918105C (en) 2023-02-28
TR201903312T4 (tr) 2019-04-22
WO2015023504A1 (en) 2015-02-19
ME03348B (me) 2019-10-20
SG11201600481UA (en) 2016-02-26
CN105451760A (zh) 2016-03-30
AU2014306956A1 (en) 2016-02-04
JP2024129139A (ja) 2024-09-26
EP3033101A4 (en) 2017-07-12
WO2015023504A8 (en) 2015-09-24
JP2016527324A (ja) 2016-09-08
RS58404B1 (sr) 2019-04-30
JP6746495B2 (ja) 2020-08-26
HK1225302B (en) 2017-09-08
AU2014306956B2 (en) 2019-11-21
EP3033101A1 (en) 2016-06-22
US20170198049A1 (en) 2017-07-13
CY1122132T1 (el) 2020-11-25
AU2020201327A1 (en) 2020-03-12
RU2016108723A3 (enExample) 2018-06-18
JP2020128375A (ja) 2020-08-27
HK1221644A1 (zh) 2017-06-09
MX2016001383A (es) 2016-08-03
HRP20190405T1 (hr) 2019-04-19
JP2022120009A (ja) 2022-08-17
CN111588848A (zh) 2020-08-28
PL3033101T3 (pl) 2019-06-28
SI3033101T1 (sl) 2019-04-30
US20150044202A1 (en) 2015-02-12
SMT201900163T1 (it) 2019-05-10
PT3033101T (pt) 2019-04-02
LT3033101T (lt) 2019-03-25
US9441037B2 (en) 2016-09-13

Similar Documents

Publication Publication Date Title
KR102390714B1 (ko) 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
KR102337599B1 (ko) 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
KR102337601B1 (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
RU2840902C2 (ru) Способы нормализации симптомов астмы с применением бенрализумаба
HK40064505A (en) Methods for improving asthma symptoms using benralizumab
HK40013807A (en) Methods for improving asthma symptoms using benralizumab
HK40013807B (en) Methods for improving asthma symptoms using benralizumab
HK1225302A1 (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK40035226A (en) Methods for reducing exacerbation rates of asthma using benralizumab
HK1225303B (en) Methods for improving asthma symptoms using benralizumab

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220420

Application number text: 1020167006559

Filing date: 20160311

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220520

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220622

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20221212

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220622

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I